Should I buy or sell ALX Oncology stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks .

What is ALX Oncology's stock price target for 2024?

8 Wall Street research analysts have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they predict the company's stock price to reach $20.07 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts .

How have ALXO shares performed in 2023?

ALX Oncology's stock was trading at $11.27 on January 1st, 2023. Since then, ALXO stock has increased by 8.8% and is now trading at $12.26. View the best growth stocks for 2023 here .

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our ALXO earnings forecast .

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.38.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON) , Deere & Company (DE) , GrowGeneration (GRWG) , Innovative Industrial Properties (IIPR) , Immunomedics (IMMU) , Teck Resources (TECK) , Abbott Laboratories (ABT) , Ability (ABIL) , AbbVie (ABBV) and

When did ALX Oncology IPO?

(ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (13.59%), Federated Hermes Inc. (0.61%), Charles Schwab Investment Management Inc. (0.34%), Hsbc Holdings PLC (0.09%), Barclays PLC (0.07%) and J.P. Morgan Private Wealth Advisors LLC (0.05%). Insiders that own company stock include G Walmsley Graham, Jason Lettmann , Jaume Pons , Lsv Associates, Llc, Peter S Garcia, Peter S Garcia , Shelly Pinto and Sophia Randolph . View institutional ownership trends .

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ALX Oncology Stock Price, News & Analysis (NASDAQ:ALXO)

$12.26

+3.01 (+32.54%)

(As of 12/8/2023 ET)

Compare

Today's Range: $10.15
▼
$13.50
50-Day Range: $4.81
▼
$12.26
52-Week Range: $3.94
▼
$13.50

Volume: 3.85 million shs
Average Volume: 535,468 shs
Market Capitalization: $610.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.07

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 63.7% Upside
$20.07 Price Target
Short Interest: Bearish
17.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.61) to ($3.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

310th out of 945 stocks

Pharmaceutical Preparations Industry

106th out of 423 stocks

4.5

Analyst's Opinion

Consensus Rating
ALX Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.07, ALX Oncology has a forecasted upside of 63.7% from its current price of $12.26.
Amount of Analyst Coverage
ALX Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
17.50% of the float of ALX Oncology has been sold short.
Short Interest Ratio / Days to Cover
ALX Oncology has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ALX Oncology has recently increased by 2.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ALX Oncology does not currently pay a dividend.
Dividend Growth
ALX Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALXO.

2.0

News and Social Media Coverage

News Sentiment
ALX Oncology has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ALX Oncology this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ALX Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.37% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ALX Oncology are expected to grow in the coming year, from ($3.61) to ($3.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ALX Oncology is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ALX Oncology is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ALX Oncology has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALXO Stock News Headlines

December 9, 2023 | americanbankingnews.com

ALX Oncology (NASDAQ:ALXO) Upgraded to "Buy" at Jefferies Financial Group

December 9, 2023 | msn.com

Jefferies Upgrades Alx Oncology Holdings (ALXO)

December 9, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 8, 2023 | msn.com

Jefferies raises ALX Oncology to buy, cites upcoming catalysts

December 8, 2023 | msn.com

ALX Oncology shares jump 9% after Jefferies upgrade

November 30, 2023 | americanbankingnews.com

ALX Oncology (NASDAQ:ALXO) and Keros Therapeutics (NASDAQ:KROS) Head-To-Head Comparison

November 15, 2023 | markets.businessinsider.com

Promising Interim Data and Financial Stability Prompt Buy Rating for ALX Oncology Holdings

November 13, 2023 | finance.yahoo.com

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 13, 2023 | finance.yahoo.com

ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments

November 1, 2023 | finance.yahoo.com

ALX Oncology Announces November Investor Conference Participation

October 12, 2023 | fool.com

ALX Oncology (NASDAQ: ALXO)

October 11, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on ALX Oncology Holdings (ALXO)

October 10, 2023 | finance.yahoo.com

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 9, 2023 | finance.yahoo.com

While institutions invested in ALX Oncology Holdings Inc. (NASDAQ:ALXO) benefited from last week's 74% gain, private equity firms stood to gain the most

October 9, 2023 | msn.com

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

October 6, 2023 | msn.com

Alx Oncology Holdings (ALXO) Price Target Increased by 13.11% to 16.98

October 5, 2023 | benzinga.com

What's Going On With ALX Oncology Stock?

October 5, 2023 | finance.yahoo.com

Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More

October 5, 2023 | finance.yahoo.com

ALX Oncology Announces Pricing of Public Offering

October 4, 2023 | finance.yahoo.com

ALX Oncology Announces Proposed Public Offering

October 4, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for ALX Oncology Holdings

October 3, 2023 | proactiveinvestors.com

ALX Oncology stock doubles on early data from phase II cancer trial

October 3, 2023 | msn.com

Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?

October 3, 2023 | finance.yahoo.com

Point Biopharma, ALX Oncology surge premarket; McCormick, Airbnb falls

October 3, 2023 | finance.yahoo.com

Why ALX Oncology Stock Is Skyrocketing Today

October 3, 2023 | msn.com

Biggest stock movers today: ALX Oncology Holdings, Sibanye Stillwater and more

See More Headlines

Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALXO
CUSIP: N/A
CIK: 1810182
Web: www.alxoncology.com
Phone: 650-466-7125
Fax: N/A
Employees: 71
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.07
High Stock Price Target: $34.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +66.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.07%
Return on Assets: -53.14%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 5.66
Quick Ratio: 5.66

Sales & Book Value

Annual Sales: $1.18 million
Price / Sales: 517.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.46 per share
Price / Book: 1.90

Miscellaneous

Outstanding Shares: 49,819,000
Free Float: 24,760,000
Market Cap: $610.78 million
Optionable: Not Optionable
Beta: 1.39

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Corey S. Goodman Ph.D. (Age 71)
Executive Chairman
Comp: $84k
Mr. Jason W. Lettmann (Age 46)
CEO & Director
Comp: $60.5k
Dr. Jaume Pons Ph.D. (Age 57)
Founder, President, Director & Chief Scientific Officer
Comp: $856.29k
Mr. Peter S. Garcia M.B.A. (Age 61)
Chief Financial Officer
Comp: $631.11k
Dr. Sophia Randolph M.D. (Age 55)
Ph.D., Chief Medical Officer & Director
Comp: $637.24k
Dr. Michael Chang Ph.D.
Vice President of Operations
Ms. Shelly Pinto (Age 47)
Senior VP of Finance & Chief Accounting Officer
Comp: $508.26k
Dr. Christopher Byrd J.D.
Ph.D., General Counsel
Dr. Athanasios Tsiatis M.D.
Senior Vice President of Clinical Development
Dr. Lin Yeong-Liang M.D.
M.S., Senior Vice President of Drug Safety & Pharmacovigilance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALXO shares.
View ALXO analyst ratings or view top-rated stocks.
What is ALX Oncology's stock price target for 2024?: 8 Wall Street research analysts have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they predict the company's stock price to reach $20.07 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts.
How have ALXO shares performed in 2023?: ALX Oncology's stock was trading at $11.27 on January 1st, 2023. Since then, ALXO stock has increased by 8.8% and is now trading at $12.26.
View the best growth stocks for 2023 here.
When is ALX Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ALXO earnings forecast.
How were ALX Oncology's earnings last quarter?: ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.38.

What other stocks do shareholders of ALX Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and
When did ALX Oncology IPO?: (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.
Who are ALX Oncology's major shareholders?: ALX Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (13.59%), Federated Hermes Inc. (0.61%), Charles Schwab Investment Management Inc. (0.34%), Hsbc Holdings PLC (0.09%), Barclays PLC (0.07%) and J.P. Morgan Private Wealth Advisors LLC (0.05%). Insiders that own company stock include G Walmsley Graham, Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends.
How do I buy shares of ALX Oncology?: Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial